PL2720698T3 - Pozytywne modulatory allosteryczne nikotynowego receptora acetylocholiny - Google Patents
Pozytywne modulatory allosteryczne nikotynowego receptora acetylocholinyInfo
- Publication number
- PL2720698T3 PL2720698T3 PL12729555T PL12729555T PL2720698T3 PL 2720698 T3 PL2720698 T3 PL 2720698T3 PL 12729555 T PL12729555 T PL 12729555T PL 12729555 T PL12729555 T PL 12729555T PL 2720698 T3 PL2720698 T3 PL 2720698T3
- Authority
- PL
- Poland
- Prior art keywords
- indan
- schizophrenia
- piperazine
- trimethyl
- chloro
- Prior art date
Links
- BYPMJBXPNZMNQD-PZJWPPBQSA-N Zicronapine Chemical compound C1C(C)(C)N(C)CCN1[C@H]1C2=CC(Cl)=CC=C2[C@H](C=2C=CC=CC=2)C1 BYPMJBXPNZMNQD-PZJWPPBQSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161498653P | 2011-06-20 | 2011-06-20 | |
| DKPA201100465 | 2011-06-20 | ||
| PCT/EP2012/061779 WO2012175531A1 (en) | 2011-06-20 | 2012-06-20 | Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia |
| EP12729555.8A EP2720698B1 (en) | 2011-06-20 | 2012-06-20 | Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2720698T3 true PL2720698T3 (pl) | 2019-01-31 |
Family
ID=58794324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12729555T PL2720698T3 (pl) | 2011-06-20 | 2012-06-20 | Pozytywne modulatory allosteryczne nikotynowego receptora acetylocholiny |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9610287B2 (enExample) |
| EP (1) | EP2720698B1 (enExample) |
| JP (1) | JP6140151B2 (enExample) |
| KR (1) | KR101900989B1 (enExample) |
| CN (1) | CN103608015A (enExample) |
| AU (1) | AU2012274150B2 (enExample) |
| BR (1) | BR112013032178A2 (enExample) |
| CA (1) | CA2838055C (enExample) |
| DK (1) | DK2720698T3 (enExample) |
| ES (1) | ES2694298T3 (enExample) |
| HR (1) | HRP20181684T1 (enExample) |
| IL (1) | IL230060A (enExample) |
| JO (1) | JO3421B1 (enExample) |
| LT (1) | LT2720698T (enExample) |
| MX (1) | MX349754B (enExample) |
| PL (1) | PL2720698T3 (enExample) |
| RS (1) | RS57944B1 (enExample) |
| RU (1) | RU2613177C2 (enExample) |
| SI (1) | SI2720698T1 (enExample) |
| SM (1) | SMT201800567T1 (enExample) |
| TW (1) | TWI552751B (enExample) |
| WO (1) | WO2012175531A1 (enExample) |
| ZA (1) | ZA201309617B (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7402400B2 (en) | 2001-07-03 | 2008-07-22 | Regents Of The University Of California | Mammalian sweet taste receptors |
| BR0015634A (pt) | 1999-11-17 | 2002-12-31 | Mendel Biotechnology Inc | Planta, polinucleotìdeo, vetor, célula, composição, polipeptìdeo, métodos para produzir uma planta e para identificar um fator que é modulado por, ou interage com, um polipeptìdeo codificado por um polinucleotìdeo, uma molécula que module a atividade ou a expressão de um polinucleotìdeo ou polipeptìdeo de interesse e uma sequência similar ou homóloga a um ou mais polinucleotìdeos e sistema integrado, meio computadorizado ou legìvel em computador |
| US6458538B1 (en) | 1999-12-14 | 2002-10-01 | Ptc Therapeutics, Inc. | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay |
| TW201006846A (en) | 2000-03-07 | 2010-02-16 | Senomyx Inc | T1R taste receptor and genes encidung same |
| AU2001286617A1 (en) | 2000-08-22 | 2002-03-04 | Luc Adam | Genes for modifying plant traits iv |
| US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
| US7883856B2 (en) | 2001-04-05 | 2011-02-08 | Senomyx Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
| EP2293067B1 (en) | 2001-06-26 | 2016-04-20 | Senomyx, Inc. | T1R hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds |
| US7871619B2 (en) | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| EP2436774A3 (en) | 2002-08-01 | 2012-06-13 | The Regents of The University of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| WO2004016733A2 (en) | 2002-08-16 | 2004-02-26 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| BR0314389A (pt) | 2002-09-18 | 2005-07-12 | Mendel Biotechnology Inc | Polinucleotìdeos e polipeptìdeos em plantas |
| EP2319524B1 (en) | 2003-05-30 | 2013-08-21 | Agensys, Inc. | Prostate stem cell antigen (PSCA) variants and subsequences thereof |
| EP1694816B1 (en) | 2003-11-07 | 2013-08-28 | Ciphergen Biosystems, Inc. | Biomarkers for alzheimer's disease |
| AU2004304665B2 (en) | 2003-12-24 | 2009-03-12 | Novo Nordisk A/S | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR |
| US20050226865A1 (en) | 2004-04-02 | 2005-10-13 | Regents Of The University Of California | Methods and compositions for treating and preventing diseases associated with alphavbeta5 integrin |
| US7939251B2 (en) | 2004-05-06 | 2011-05-10 | Roche Molecular Systems, Inc. | SENP1 as a marker for cancer |
| MXPA06013834A (es) | 2004-05-28 | 2007-03-01 | Agensys Inc | Anticuerpos y moleculas relacionadas que enlazan a proteinas psca. |
| DK2453024T3 (en) | 2004-06-21 | 2018-02-12 | Univ Leland Stanford Junior | Genes and conduits that are differentially expressed in bipolar disorder and / or major depressive disorder |
| US7850960B2 (en) | 2004-12-30 | 2010-12-14 | University Of Washington | Methods for regulation of stem cells |
| JP2008528060A (ja) | 2005-01-27 | 2008-07-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ボツリヌス神経毒素を中和する治療的モノクローナル抗体 |
| EP3300739A3 (en) | 2005-03-31 | 2018-07-18 | Agensys, Inc. | Antibodies and related molecules that bind to 161p2f10b proteins |
| NZ565172A (en) | 2005-07-19 | 2012-12-21 | Stemgen S P A | Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS |
| WO2007047988A2 (en) | 2005-10-20 | 2007-04-26 | Senomyx, Inc. | Chimeric human sweet-umami and umami-sweet taste receptors |
| UA94922C2 (ru) | 2005-11-07 | 2011-06-25 | Зе Скріпс Рісьорч Інстітьют | Способ регулирования специфичности сигнализации тканевого фактора у млекопитающего, которое нуждается в этом, способ идентификации агента, который специфически ингибирует сигнализацию тканевого фактора |
| WO2007059064A2 (en) | 2005-11-12 | 2007-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Fgf2-related methods for diagnosing and treating depression |
| US8288354B2 (en) | 2005-12-28 | 2012-10-16 | The Scripps Research Institute | Natural antisense and non-coding RNA transcripts as drug targets |
| WO2007109347A2 (en) | 2006-03-21 | 2007-09-27 | The Regents Of The University Of California | N-cadherin and ly6 e: targets for cancer diagnosis and therapy |
| US20100278821A1 (en) | 2006-03-21 | 2010-11-04 | The Regents Of The University Of California | N-cadherin: target for cancer diagnosis and therapy |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| EP2061900A2 (en) | 2006-08-25 | 2009-05-27 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
| NZ575090A (en) | 2006-09-06 | 2012-02-24 | Univ California | Molecular diagnosis and classification of malignant melanoma using RGS1, ARPC2, FN1, SPP1 and WNT-2 polypeptide markers |
| WO2008127314A1 (en) | 2006-11-22 | 2008-10-23 | President And Fellows Of Harvard College | High-sensitivity nanoscale wire sensors |
| IN2009KN04568A (enExample) | 2007-06-01 | 2015-08-28 | Univ Princeton | |
| ES2416719T3 (es) | 2007-08-13 | 2013-08-02 | Baxter International Inc. | Modulación por IVIG de quimioquinas para el tratamiento de la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson |
| US7939671B2 (en) | 2007-08-21 | 2011-05-10 | Senomyx, Inc. | Compounds that inhibit (block) bitter taste in composition and use thereof |
| CA2971794C (en) | 2007-10-04 | 2020-03-24 | Zymogenetics, Inc. | B7 family member zb7h6 and related compositions and methods |
| EP2924435A3 (en) | 2007-10-22 | 2015-11-04 | The Regents of The University of California | Biomarkers for prenatal diagnosis of congenital cytomegalovirus |
| WO2010008411A1 (en) | 2007-11-09 | 2010-01-21 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
| SG10202103401QA (en) | 2008-03-17 | 2021-05-28 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| EP2268654B1 (en) | 2008-04-21 | 2017-01-25 | The Regents Of The University Of California | Selective high-affinity polydentate ligands and methods of making such |
| US20110262485A1 (en) | 2008-08-04 | 2011-10-27 | University Of Miami | Sting (stimulator of interferon genes), a regulator of innate immune responses |
| US20110287026A1 (en) | 2008-09-23 | 2011-11-24 | President And Fellows Of Harvard College | Sirt4 and uses thereof |
| WO2010054189A1 (en) | 2008-11-06 | 2010-05-14 | University Of Miami | Role of soluble upar in the pathogenesis of proteinuric kidney disease |
| EP2352847B1 (en) | 2008-11-10 | 2014-01-08 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Gene signature for predicting prognosis of patients with solid tumors |
| CA3128456A1 (en) | 2008-12-03 | 2010-06-10 | The Scripps Research Institute | Compounds and methods for stabilizing cell cultures |
| CA2747398C (en) | 2008-12-17 | 2023-06-20 | The Scripps Research Institute | Generation and maintenance of stem cells |
| DK2411410T3 (en) | 2009-03-27 | 2015-09-07 | Gojo Ind Inc | Compositions and methods for screening and use of compounds which counteract the track-surface interactions |
| JP5755647B2 (ja) | 2009-07-24 | 2015-07-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | αｖβ５インテグリンに関連する疾患の処置および予防のための方法および組成物 |
| CN105911275B (zh) | 2009-08-14 | 2018-06-29 | 加利福尼亚大学董事会 | 诊断自闭症的试剂盒 |
| US20120148604A1 (en) | 2009-08-20 | 2012-06-14 | Transposagen Biopharmaceuticals, Inc. | Trp inhibitors and uses thereof |
| US9297796B2 (en) | 2009-09-24 | 2016-03-29 | President And Fellows Of Harvard College | Bent nanowires and related probing of species |
| ES2365343B1 (es) | 2009-11-19 | 2012-07-10 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de cd98 como marcador de receptividad endometrial. |
| US20130137584A1 (en) | 2010-02-01 | 2013-05-30 | The Regents Of The University Of California | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies |
| WO2012052391A1 (en) | 2010-10-19 | 2012-04-26 | Glaxo Group Limited | Polypeptide with jmjd3 catalytic activity |
| WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
| WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
| US20120301904A1 (en) | 2011-04-26 | 2012-11-29 | Prosetta Antiviral, Inc | Multiprotein assemblies |
| US9408832B2 (en) | 2012-03-14 | 2016-08-09 | University Of Central Florida Research Foundation, Inc. | LIM kinasemodulating agents for neurofibromatoses therapy and methods for screening for same |
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| JP2015516400A (ja) | 2012-04-24 | 2015-06-11 | ユニバーシティー オブ マイアミＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ | 侵襲的かつ多剤耐性の病原体に対するパーフォリン２の防御 |
| US20150164800A1 (en) | 2012-07-25 | 2015-06-18 | Xetrios Therapeutics, Inc. | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine |
| EP2890370B1 (en) | 2012-08-31 | 2019-10-09 | The Regents of the University of California | Agents useful for treating obesity, diabetes and related disorders |
| AU2013204200B2 (en) | 2012-10-11 | 2016-10-20 | Brandeis University | Treatment of amyotrophic lateral sclerosis |
| US20140120116A1 (en) | 2012-10-26 | 2014-05-01 | The Chinese University Of Hong Kong | Treatment of cancer using smad3 inhibitor |
| US20140243356A1 (en) | 2013-02-07 | 2014-08-28 | The Regents Of The University Of California | Use of translational profiling to identify target molecules for therapeutic treatment |
| WO2014144844A1 (en) | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY |
| US10919929B2 (en) | 2013-12-11 | 2021-02-16 | Sloan-Kettering Institute For Cancer Research | Glucocorticoid inhibitors for treatment of prostate cancer |
| US10280169B2 (en) | 2013-12-11 | 2019-05-07 | Biogen Ma Inc. | Biaryl bruton's tyrosine kinase inhibitors |
| WO2015136509A2 (en) | 2014-03-14 | 2015-09-17 | Genesis Theranostix Korlatolt Felelossegu Tarsasag | Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy |
| US10196701B2 (en) | 2015-06-01 | 2019-02-05 | The Penn State Research Foundation | Hepatitis B virus capsid assembly |
| EP3314260B1 (en) | 2015-06-24 | 2021-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for detecting protein-protein interactions |
| WO2018036503A1 (en) | 2016-08-25 | 2018-03-01 | The Chinese University Of Hong Kong | Fecal bacterial markers for colorectal cancer |
| RU2019121922A (ru) | 2016-12-15 | 2021-01-18 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Композиции и способы лечения рака |
| EP3601326A4 (en) | 2017-03-20 | 2020-12-16 | The Broad Institute, Inc. | COMPOUNDS AND METHODS OF REGULATING INSULIN SECRETION |
| EP3606548A4 (en) | 2017-04-04 | 2021-03-24 | Loma Linda University | BIOLOGICAL PREPARATION FOR TREATMENT OF CANCER |
| WO2019207587A1 (en) | 2018-04-26 | 2019-10-31 | Technion Research & Development Foundation Limited | A device and a method for determining cell indentation activity |
| US20210395751A1 (en) | 2018-10-31 | 2021-12-23 | The University Of Sydney | Compositions and methods for treating viral infections |
| US11325978B2 (en) | 2018-11-06 | 2022-05-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for treating beta-globinopathies |
| EP4247427A4 (en) | 2020-11-19 | 2025-04-09 | The Chinese University of Hong Kong | Assessing risk for colorectal adenoma recurrence by noninvasive means |
| WO2023081167A2 (en) | 2021-11-02 | 2023-05-11 | The Regents Of The University Of California | P-selectin mutants and modulation of integrin-mediated signaling |
| WO2023146807A1 (en) | 2022-01-25 | 2023-08-03 | The Regents Of The University Of California | Vegf mutants and modulation of integrin-mediated signaling |
| WO2024197185A1 (en) | 2023-03-21 | 2024-09-26 | The Broad Institute, Inc. | Methods and compositions for dissecting organelle physiology |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK55192D0 (da) | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
| AU2004265021B2 (en) | 2003-08-18 | 2010-05-27 | H. Lundbeck A/S | Succinate and malonate salt of trans-4-(IR,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
| KR20070014184A (ko) | 2004-04-22 | 2007-01-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 성기능 장애 치료용 신규 약제학적 조성물 ⅱ |
| KR101283946B1 (ko) * | 2005-07-18 | 2013-07-15 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 약물 함유 임플란트 및 그의 사용 방법 |
| CA2722374A1 (en) * | 2008-05-07 | 2009-11-12 | H. Lundbeck A/S | Method for treating cognitive deficits |
| BRPI0919165A2 (pt) * | 2008-10-03 | 2015-12-08 | Lundbeck & Co As H | composição farmacêutica,e, uso de um composto |
| EP2453870A2 (en) * | 2009-06-24 | 2012-05-23 | MSD Oss B.V. | Injectable formulations containing asenapine and method of treatment using same |
-
2012
- 2012-06-19 TW TW101121870A patent/TWI552751B/zh not_active IP Right Cessation
- 2012-06-19 JO JOP/2012/0162A patent/JO3421B1/ar active
- 2012-06-20 BR BR112013032178A patent/BR112013032178A2/pt not_active Application Discontinuation
- 2012-06-20 WO PCT/EP2012/061779 patent/WO2012175531A1/en not_active Ceased
- 2012-06-20 RU RU2014101482A patent/RU2613177C2/ru active
- 2012-06-20 MX MX2013014978A patent/MX349754B/es active IP Right Grant
- 2012-06-20 PL PL12729555T patent/PL2720698T3/pl unknown
- 2012-06-20 EP EP12729555.8A patent/EP2720698B1/en active Active
- 2012-06-20 HR HRP20181684TT patent/HRP20181684T1/hr unknown
- 2012-06-20 CN CN201280029452.1A patent/CN103608015A/zh active Pending
- 2012-06-20 SM SM20180567T patent/SMT201800567T1/it unknown
- 2012-06-20 US US14/126,499 patent/US9610287B2/en active Active
- 2012-06-20 DK DK12729555.8T patent/DK2720698T3/en active
- 2012-06-20 AU AU2012274150A patent/AU2012274150B2/en not_active Ceased
- 2012-06-20 RS RS20181311A patent/RS57944B1/sr unknown
- 2012-06-20 KR KR1020137033338A patent/KR101900989B1/ko not_active Expired - Fee Related
- 2012-06-20 ES ES12729555.8T patent/ES2694298T3/es active Active
- 2012-06-20 SI SI201231436T patent/SI2720698T1/sl unknown
- 2012-06-20 LT LTEP12729555.8T patent/LT2720698T/lt unknown
- 2012-06-20 JP JP2014516318A patent/JP6140151B2/ja active Active
- 2012-06-20 CA CA2838055A patent/CA2838055C/en not_active Expired - Fee Related
-
2013
- 2013-12-19 ZA ZA2013/09617A patent/ZA201309617B/en unknown
- 2013-12-19 IL IL230060A patent/IL230060A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN103608015A (zh) | 2014-02-26 |
| KR20140033419A (ko) | 2014-03-18 |
| AU2012274150B2 (en) | 2016-10-06 |
| EP2720698B1 (en) | 2018-10-03 |
| ES2694298T3 (es) | 2018-12-19 |
| LT2720698T (lt) | 2018-11-12 |
| JP2014517050A (ja) | 2014-07-17 |
| SI2720698T1 (sl) | 2018-12-31 |
| EP2720698A1 (en) | 2014-04-23 |
| TWI552751B (zh) | 2016-10-11 |
| RU2014101482A (ru) | 2015-07-27 |
| DK2720698T3 (en) | 2018-11-26 |
| JO3421B1 (ar) | 2019-10-20 |
| SMT201800567T1 (it) | 2018-11-09 |
| JP6140151B2 (ja) | 2017-05-31 |
| TW201306840A (zh) | 2013-02-16 |
| WO2012175531A1 (en) | 2012-12-27 |
| AU2012274150A1 (en) | 2014-01-09 |
| US9610287B2 (en) | 2017-04-04 |
| KR101900989B1 (ko) | 2018-09-20 |
| RU2613177C2 (ru) | 2017-03-15 |
| MX349754B (es) | 2017-08-11 |
| BR112013032178A2 (pt) | 2016-12-20 |
| CA2838055A1 (en) | 2012-12-27 |
| US20140194409A1 (en) | 2014-07-10 |
| MX2013014978A (es) | 2014-04-10 |
| HRP20181684T1 (hr) | 2018-12-14 |
| ZA201309617B (en) | 2015-04-29 |
| IL230060A (en) | 2017-10-31 |
| CA2838055C (en) | 2021-01-26 |
| RS57944B1 (sr) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201309617B (en) | Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia | |
| IL253225A0 (en) | Sulfamoyl-arylamides and their use as drugs to treat jaundice b | |
| PL2672966T3 (pl) | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania | |
| SI2729151T1 (sl) | Farmacevtski sestavek, postopki za zdravljenje in njihove uporabe | |
| IL221160A (en) | 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation | |
| EP2665479A1 (en) | Methods and drug products for treating alzheimer's disease | |
| HK1197159A1 (en) | Pirfenidone and anti-fibrotic therapy in selected patients | |
| IL230957A0 (en) | Pharmacy methods and preparations for the treatment of an eye disease in a patient | |
| PL2726470T3 (pl) | Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych | |
| EP2766728A4 (en) | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONAROPATHY | |
| EP2785335B8 (en) | Methods and pharmaceutical compositions for the treatment of darier disease | |
| EP2789607A4 (en) | PYRIDONE DERIVATIVE AND MEDICAMENT THEREFOR | |
| PT2720698T (pt) | Método de administração de 4-((1r,3s)-6-cloro-3-fenil-indan-1-il)- 1,2,2-trimetil-piperazina e dos seus sais no tratamento da esquizofrenia | |
| IL238071B (en) | Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease | |
| IL228891A (en) | 3-carboxylic salts-n-ethyl n, n-dimethylpropane-1-amine for use in the treatment of cardiovascular disease | |
| SI2699545T1 (sl) | Novi amino-pirolinski derivati in uporaba le-teh pri preprečevanju in/ali zdravljenju metaboličnega sindroma | |
| EP2789332A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING DIAMINODIPHENYLSULFONE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH BONE MASS REDUCTION | |
| HK1193342A (en) | Pharmaceutical combination for use in the treatment of diabetes type 2 | |
| AU2011904233A0 (en) | Use of meloxicam in the treatment of post operative sheep | |
| PT3539540T (pt) | Inibidor de sglt2 1-cloro-4-(beta-d-glucopiranos-1-il)-2-[4-((s)-tetra-hidrofurano-3-iloxi)-benzil]-benzeno em combinação com insulina para utilização num método para redução do risco de hipoglicemia | |
| ZA201307614B (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease | |
| ZA201505093B (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis | |
| HK1191279A (en) | 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma | |
| HK1189818A (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| TN2013000404A1 (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease |